Parabilis Medicines is ambitious, but it has Regeneron on its side already.

It has been a banner year for biotech buyouts, and these are two of the prime targets.

Intellia's CRISPR pipeline and Omeros's newly approved therapy each bring unique risk and reward profiles, see how their ...

Viking Therapeutics aspires to take market share from both Eli Lilly and Novo Nordisk, and it might succeed.

In interviews as well as a panel at BIO’s annual meeting, investors and life sciences bankers predicted an acceleration in ...

IBB, one of the largest exchange-traded funds focused on biotechnology, manages approximately $8.28 billion in assets and ...

Patent cliffs are forcing Big Pharma to hunt for revenue-producing biotech assets, and three names keep surfacing in deal ...

Kardigan (KARD) didn’t just raise $400 million. The heart-drug developer sent a new signal to biotech investors about what ...

Three mid-cap biotechs have become prime acquisition targets, but only one offers what big pharma is hunting for most.

Ernst & Young's 2026 biotech report shows 13% revenue growth to $232B, but US policy shifts, patent cliffs and uneven ...

Biopharma dealmaking is driven by pressure to top up drug pipelines ahead of major patent expirations later this decade.

The new outfit, called Saturnus Bio, was announced today by Merck KGaA, and will focus on developing medicines for rare ...